Ketorolac or ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) in the family of heterocyclic acetic acid derivatives, used as an analgesic. Ketorolac was developed in 1989 by Syntex Corp. (now Roche Bioscience, which is a wholly owned subsidiary of Roche holding Ltd., the parent company of Roche). It was approved by FDA on 30 November 1989 and introduced as Toradol by Syntex. The ophthalmic (i.e., eye-drop) form was approved by FDA on 9 November 1992 and was introduced as Acular eye drops by Allergan under license from Syntex. An intranasal formulation of ketorolac tromethamine was approved by FDA on 14 May 2010 and introduced as Sprix Nasal Spray by Daiichi Sankyo for short-term management of moderate to moderately severe pain requiring analgesia at the opioid level.

CAS：74103-06-3
中文别名：(+/-)-5-苯甲酰基-2,3-二氢-1H-吡咯并吡咯烷-1-甲酸;
英文别名：Acular;Tm-asyn;Ketoralac;Toratex;Fluoxetin;Lixidol;Dolac;KETOROLAC-D5;
分子式：C15H8D5NO3
分子量：260.299
精确质量：260.121
Psa：59.3
Logp：2.291

UNII：YZI5105V0L

外观与性状：白色结晶或白色粉末
密度：1.398 g/cm3
沸点：223.7ºC at 760 mmHg
熔点：160-161°C
闪点：89.1ºC
折射率：1.659

危险品运输编码：3249
危险类别：6.1(a)
包装等级：II

生产方法
方法1:吡咯和二甲硫醚在N-氯代丁二酰亚胺作用下,得到2-(甲硫基)吡咯。2-(甲硫基)吡咯在含三氯氧磷的二氯乙烷溶液中,在回流下用苯甲酰二甲胺进行酰化,得到2-(甲硫基)-5-苯甲酰基毗咯。该化合物和螺二氧杂辛烷二酮缩合得化合物(I)。化合物(I)先氧化,然后甲醇解,得二酯化物(Ⅱ)。(Ⅱ)在二甲基甲酰胺中,氢化钠作用下环合得到化合物(Ⅲ)。(Ⅲ)水解并脱羧得到酮咯酸。 1.消炎镇痛药,并有抗血小板凝集作用。
用途
1.消炎镇痛药,并有抗血小板凝集作用。